以“不可成药”的驱动蛋白KRAS为靶点，作为前列腺癌的潜在治疗方法。
Targeting the "Undruggable" Driver Protein, KRAS, as Potential Therapy in Prostate Cancer.
作者信息
Kargbo Robert B
机构信息
Usona Institute, Fitchburg, Wisconsin 53711-5300, United States.
出版信息
ACS Med Chem Lett. 2023 Mar 20;14(4):365-366. doi: 10.1021/acsmedchemlett.3c00076. eCollection 2023 Apr 13.
Abstract
In spite of the progress made in the development of KRAS inhibitors, there is still continued interest to develop inhibitors of other KRAS such as KRAS for the treatment of diseases, including prostate cancer, colorectal cancer, and non-small-cell lung cancer. This Patent Highlight provides exemplary compounds having activity as inhibitors of G12D mutant KRAS protein.
摘要
尽管在KRAS抑制剂的开发方面取得了进展，但人们仍持续关注开发其他KRAS抑制剂，如KRAS，用于治疗包括前列腺癌、结直肠癌和非小细胞肺癌在内的疾病。本专利亮点提供了具有作为G12D突变型KRAS蛋白抑制剂活性的示例性化合物。
相似文献
1
Targeting the "Undruggable" Driver Protein, KRAS, as Potential Therapy in Prostate Cancer.以“不可成药”的驱动蛋白KRAS为靶点，作为前列腺癌的潜在治疗方法。
ACS Med Chem Lett. 2023 Mar 20;14(4):365-366. doi: 10.1021/acsmedchemlett.3c00076. eCollection 2023 Apr 13.
2
KRAS G12D targeted therapies for pancreatic cancer: Has the fortress been conquered?针对胰腺癌的KRAS G12D靶向疗法：堡垒已被攻克了吗？
Front Oncol. 2022 Nov 29;12:1013902. doi: 10.3389/fonc.2022.1013902. eCollection 2022.
3
Salvianolic acid F suppresses KRAS-dependent lung cancer cell growth through the PI3K/AKT signaling pathway.丹酚酸F通过PI3K/AKT信号通路抑制KRAS依赖的肺癌细胞生长。
Phytomedicine. 2023 Dec;121:155093. doi: 10.1016/j.phymed.2023.155093. Epub 2023 Sep 17.
4
Glimmers of hope for targeting oncogenic KRAS-G12D.靶向致癌性KRAS-G12D的希望曙光。
Cancer Gene Ther. 2023 Mar;30(3):391-393. doi: 10.1038/s41417-022-00561-3. Epub 2022 Nov 21.
5
Light at the end of the tunnel: Clinical features and therapeutic prospects of KRAS mutant subtypes in non-small-cell lung cancer.曙光在前：非小细胞肺癌中KRAS突变亚型的临床特征与治疗前景
Front Genet. 2022 Oct 21;13:890247. doi: 10.3389/fgene.2022.890247. eCollection 2022.
6
Molecular profile of KRAS G12C-mutant colorectal and non-small-cell lung cancer.KRAS G12C 突变型结直肠癌和非小细胞肺癌的分子特征。
BMC Cancer. 2021 Feb 25;21(1):193. doi: 10.1186/s12885-021-07884-8.
7
Cetuximab Enhances the Efficacy of MRTX1133, a Novel KRAS Inhibitor, in Colorectal Cancer Treatment.西妥昔单抗增强新型 KRAS 抑制剂 MRTX1133 在结直肠癌治疗中的疗效。
Anticancer Res. 2023 Oct;43(10):4341-4348. doi: 10.21873/anticanres.16629.
8
Targeting KRAS in PDAC: A New Way to Cure It?在胰腺癌中靶向KRAS：一种新的治愈方法？
Cancers (Basel). 2022 Oct 11;14(20):4982. doi: 10.3390/cancers14204982.
9
Identification of Dietary Bioflavonoids as Potential Inhibitors against KRAS G12D Mutant-Novel Insights from Computer-Aided Drug Discovery.鉴定膳食生物类黄酮作为KRAS G12D突变体的潜在抑制剂——计算机辅助药物发现的新见解
Curr Issues Mol Biol. 2023 Mar 6;45(3):2136-2156. doi: 10.3390/cimb45030137.
10
Multiple medicinal chemistry strategies of targeting KRAS: State-of-the art and future directions.靶向 KRAS 的多种药物化学策略：现状与未来方向。
Bioorg Chem. 2024 Mar;144:107092. doi: 10.1016/j.bioorg.2023.107092. Epub 2024 Jan 4.
本文引用的文献
1
Targeting the 'Undruggable' Driver Protein, KRAS, in Epithelial Cancers: Current Perspective.针对上皮性癌症中的“不可成药”驱动蛋白 KRAS：当前视角。
Cells. 2023 Feb 15;12(4):631. doi: 10.3390/cells12040631.
2
KRAS G12D mutation in Brunner gland adenoma.布伦纳腺腺瘤中的KRAS G12D突变
BMJ Case Rep. 2023 Jan 27;16(1):e252160. doi: 10.1136/bcr-2022-252160.
3
KRAS G12D targeted therapies for pancreatic cancer: Has the fortress been conquered?针对胰腺癌的KRAS G12D靶向疗法：堡垒已被攻克了吗？
Front Oncol. 2022 Nov 29;12:1013902. doi: 10.3389/fonc.2022.1013902. eCollection 2022.
4
Light at the end of the tunnel: Clinical features and therapeutic prospects of KRAS mutant subtypes in non-small-cell lung cancer.曙光在前：非小细胞肺癌中KRAS突变亚型的临床特征与治疗前景
Front Genet. 2022 Oct 21;13:890247. doi: 10.3389/fgene.2022.890247. eCollection 2022.
5
Targeting KRAS in PDAC: A New Way to Cure It?在胰腺癌中靶向KRAS：一种新的治愈方法？
Cancers (Basel). 2022 Oct 11;14(20):4982. doi: 10.3390/cancers14204982.
6
G12D Mutation Subtype in Pancreatic Ductal Adenocarcinoma: Does It Influence Prognosis or Stage of Disease at Presentation?胰腺导管腺癌中的 G12D 突变亚型：它是否影响预后或疾病的分期？
Cells. 2022 Oct 10;11(19):3175. doi: 10.3390/cells11193175.
7
Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries.《全球癌症统计数据 2020：全球 185 个国家和地区 36 种癌症的发病率和死亡率估计》。
CA Cancer J Clin. 2021 May;71(3):209-249. doi: 10.3322/caac.21660. Epub 2021 Feb 4.
Zotero 插件